Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
Phoenix, AZ US
November 6, 2015
Learning Objectives
- Assess risk and monitor response to treatment by combining classic leukemia staging methods with novel pathology biomarkers and prognostic factors
- Discuss strategies for managing side effects of novel therapies, as well as preventing infections
- Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings
- Explain the role of the Advanced Practitioner as a member of the collaborative practice team in caring for patients with CLL through the trajectory of their illness
JW Marriott Desert Ridge
5350 East Marriott Drive
Phoenix, AZ
85054
United States
Amy Goodrich, MSN, CRNP
Deborah M. Stephens, DO
Available Credit
- 1.00 AANP
- 0.67 Pharmacology
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC